WallStSmart

Aquestive Therapeutics Inc (AQST)vsViatris Inc (VTRS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 30055% more annual revenue ($14.73B vs $48.84M). VTRS leads profitability with a -4.1% profit margin vs -162.3%. VTRS earns a higher WallStSmart Score of 40/100 (D).

AQST

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: -4.23

VTRS

Hold

40

out of 100

Grade: D

Growth: 2.0Profit: 3.5Value: 3.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AQSTSignificantly Overvalued (-52.8%)

Margin of Safety

-52.8%

Fair Value

$2.50

Current Price

$3.46

$0.96 premium

UndervaluedFair: $2.50Overvalued
VTRSSignificantly Overvalued (-80.4%)

Margin of Safety

-80.4%

Fair Value

$8.94

Current Price

$19.63

$10.69 premium

UndervaluedFair: $8.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AQST1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.1110/10

Conservative balance sheet, low leverage

VTRS1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

AQST4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$491.44M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

VTRS4 concerns · Avg: 2.0/10
PEG RatioValuation
3.732/10

Expensive relative to growth rate

Return on EquityProfitability
-4.4%2/10

ROE of -4.4% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : AQST

The strongest argument for AQST centers on Debt/Equity.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book.

Bear Case : AQST

The primary concerns for AQST are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

AQST carries more volatility with a beta of 1.50 — expect wider price swings.

VTRS is growing revenue faster at -0.3% — sustainability is the question.

VTRS generates stronger free cash flow (814M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (40/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aquestive Therapeutics Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?